These CNS abnormalities were also reported in NSCLC patients treated with crizotinib (dizziness 16%; dysgeusia 18%)12 and entrectinib (dizziness 34.8%; dysgeusia 43.4%).21 Ophthalmological AEs are unique AEs that were reported in a high proportion of NSCLC patients treated with crizotinib (82%)12 and also occurred in patients treated with other ROS1 inhibitors including brigatinib,29 entrectinib,30 and lorlatinib.18 As expected, ophthalmological AEs including visual impairment and blurred vision occurred in 36 patients (28.1%) in the current trial. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.